- Home
- ILLR vs PHAR Comparison
ILLR vs PHAR Comparison
Compare ILLR & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILLR
- PHAR
- Stock Information
- Founded
- ILLR 2015
- PHAR 1988
- Country
- ILLR United States
- PHAR Netherlands
- Employees
- ILLR N/A
- PHAR N/A
- Industry
- ILLR Investment Managers
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- ILLR Finance
- PHAR Health Care
- Exchange
- ILLR Nasdaq
- PHAR Nasdaq
- Market Cap
- ILLR 663.4M
- PHAR 627.5M
- IPO Year
- ILLR N/A
- PHAR N/A
- Fundamental
- Price
- ILLR $4.13
- PHAR $8.31
- Analyst Decision
- ILLR
- PHAR Strong Buy
- Analyst Count
- ILLR 0
- PHAR 2
- Target Price
- ILLR N/A
- PHAR $33.50
- AVG Volume (30 Days)
- ILLR 1.3M
- PHAR 5.5K
- Earning Date
- ILLR 11-21-2024
- PHAR 10-24-2024
- Dividend Yield
- ILLR N/A
- PHAR N/A
- EPS Growth
- ILLR N/A
- PHAR N/A
- EPS
- ILLR N/A
- PHAR N/A
- Revenue
- ILLR $46,338,000.00
- PHAR $285,745,000.00
- Revenue This Year
- ILLR N/A
- PHAR $20.89
- Revenue Next Year
- ILLR N/A
- PHAR $11.15
- P/E Ratio
- ILLR N/A
- PHAR N/A
- Revenue Growth
- ILLR N/A
- PHAR 30.64
- 52 Week Low
- ILLR $0.66
- PHAR $6.65
- 52 Week High
- ILLR $8.86
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- ILLR N/A
- PHAR 47.75
- Support Level
- ILLR N/A
- PHAR $7.80
- Resistance Level
- ILLR N/A
- PHAR $8.91
- Average True Range (ATR)
- ILLR 0.00
- PHAR 0.39
- MACD
- ILLR 0.00
- PHAR -0.11
- Stochastic Oscillator
- ILLR 0.00
- PHAR 28.98
About ILLR Triller Group Inc. Common Stock
Triller Group Inc is a us-based company that operates its businesses through Triller Corp which operates as a technology platform and AGBA Group Holding Limited operates as an insurance and wealth distribution platform.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.